Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a monthly peer-reviewed review journal published by Nature Portfolio. It was established in 2002^[1] and covers drug discovery and development. The editor-in-chief is Peter Kirkpatrick.^[2] According to the Journal Citation Reports, the journal has a 2021 impact factor of 112.288, ranking it 1st out of 158 journals in the category "Biotechnology & Applied Microbiology"^[3] and 1st out of 279 journals in the category "Pharmacology & Pharmacy".^[4]

Nature Reviews Drug Discovery

Discipline	Pharmacology, Biotechnology
Language	English
Edited by	Peter Kirkpatrick
Publication details
History	2002–present
Publisher	Nature Portfolio
Frequency	Monthly
Impact factor	101.8 (2024)
Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt )
ISO 4	Nat. Rev. Drug Discov.
Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus · W&L
CODEN	NRDDAG
ISSN	1474-1776 (print) 1474-1784 (web)
LCCN	2002243044
OCLC no.	427380493
Links
Journal homepage Online access Online archive

Reviews are commissioned to specialists and supplemented with glossary explanations for non-specialist readers and illustrated with figures drawn by Nature's in-house art editors. Besides reviews, the journal publishes analysis articles based on existing datasets (e.g. metaanalysis), progress articles that focus on outstanding issues, and perspective articles—typically opinions or historical pieces.^[5]

See also

• Nature Biotechnology
• Annual Review of Pharmacology and Toxicology
• Pharmacological Reviews